- Home
- HIT vs INO Comparison
HIT vs INO Comparison
Compare HIT & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIT
- INO
- Stock Information
- Founded
- HIT 1964
- INO 1979
- Country
- HIT United States
- INO United States
- Employees
- HIT N/A
- INO N/A
- Industry
- HIT Specialty Insurers
- INO Medical/Dental Instruments
- Sector
- HIT Finance
- INO Health Care
- Exchange
- HIT Nasdaq
- INO Nasdaq
- Market Cap
- HIT 152.4M
- INO 136.6M
- IPO Year
- HIT 2024
- INO 1998
- Fundamental
- Price
- HIT $1.44
- INO $1.91
- Analyst Decision
- HIT Strong Buy
- INO Buy
- Analyst Count
- HIT 1
- INO 5
- Target Price
- HIT $2.50
- INO $9.00
- AVG Volume (30 Days)
- HIT 466.5K
- INO 1.4M
- Earning Date
- HIT 11-10-2025
- INO 11-10-2025
- Dividend Yield
- HIT N/A
- INO N/A
- EPS Growth
- HIT N/A
- INO N/A
- EPS
- HIT 0.02
- INO N/A
- Revenue
- HIT $30,723,490.00
- INO $182,337.00
- Revenue This Year
- HIT $70.02
- INO N/A
- Revenue Next Year
- HIT $63.39
- INO $14,751.49
- P/E Ratio
- HIT $65.25
- INO N/A
- Revenue Growth
- HIT 55.15
- INO N/A
- 52 Week Low
- HIT $0.51
- INO $1.30
- 52 Week High
- HIT $7.59
- INO $4.61
- Technical
- Relative Strength Index (RSI)
- HIT 27.64
- INO 35.72
- Support Level
- HIT $1.49
- INO $1.93
- Resistance Level
- HIT $3.05
- INO $2.11
- Average True Range (ATR)
- HIT 0.34
- INO 0.14
- MACD
- HIT -0.14
- INO -0.04
- Stochastic Oscillator
- HIT 3.99
- INO 2.16
About HIT Health In Tech Inc. Class A Common Stock
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.